Naurex
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$18.0m | Series A | ||
$38.0m | Series B | ||
$25.0m | Series C | ||
$80.0m | Series C | ||
$560m Valuation: $560m | Acquisition | ||
Total Funding | €146m |
Related Content
Recent News about Naurex
EditNaurex, a subsidiary of AbbVie, operates in the biopharmaceutical sector, focusing on developing and delivering advanced therapies for complex medical conditions. The company primarily serves healthcare providers and patients, aiming to address unmet medical needs through innovative solutions. Naurex operates in a highly regulated market, adhering to stringent legal and clinical guidelines to ensure the safety and efficacy of its products. The business model revolves around extensive research and development (R&D), clinical trials, and strategic partnerships to bring new treatments to market. Revenue is generated through the sale of approved therapies, licensing agreements, and collaborations with other pharmaceutical entities. Naurex's core competencies include expertise in biologics, small molecules, and novel drug delivery systems, positioning it as a leader in the biopharmaceutical industry.
Keywords: biopharmaceutical, therapies, clinical trials, healthcare, R&D, biologics, small molecules, drug delivery, innovation, partnerships.